Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo.

by Srdjan Vitovski, Andrew D Chantry, Michelle A Lawson, Peter I Croucher
Published 2012-01-01

Myeloma Bone Disease: The Osteoblast in the Spotlight

by Rebecca E. Andrews, Janet E. Brown, Michelle A. Lawson, Andrew D. Chantry
Published 2021-09-01

Bone Pain in Multiple Myeloma (BPMM)—A Protocol for a Prospective, Longitudinal, Observational Study

by Marta Diaz-delCastillo, Rebecca E. Andrews, Aritri Mandal, Thomas L. Andersen, Andrew D. Chantry, Anne-Marie Heegaard
Published 2021-03-01

ARQ-197, a small-molecule inhibitor of c-Met, reduces tumour burden and prevents myeloma-induced bone disease in vivo.

by Darren L Lath, Clive H Buckle, Holly R Evans, Matthew Fisher, Jenny M Down, Michelle A Lawson, Andrew D Chantry
Published 2018-01-01

NOD/SCID-GAMMA mice are an ideal strain to assess the efficacy of therapeutic agents used in the treatment of myeloma bone disease.

by Michelle A Lawson, Julia M Paton-Hough, Holly R Evans, Rebecca E Walker, William Harris, Dharshi Ratnabalan, John A Snowden, Andrew D Chantry
Published 2015-01-01

Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs

by Spyros Kolovos, Guido Nador, Bhuvan Kishore, Matthew Streetly, Neil K. Rabin, Andrew D Chantry, Kwee Yong, John Ashcroft, Stella Bowcock, Mark T. Drayson, Karthik Ramasamy, Daniel Prieto-Alhambra, Cyrus Cooper, M. Kassim Javaid, Rafael Pinedo-Villanueva
Published 2019-08-01